Authors
Latest:
Building a Healthy Learning Environment for Young Medical Professionals: Alexandria Reynolds, PhDThe undergraduate program director at the University of South Carolina discussed the shift in teaching strategies for those in neurology and why more hands-on experience serves students better. [WATCH TIME: 5 minutes]
Latest:
Enacting Necessary Changes to the MS Care Model: Mona Bostick, RDN, LDN, MSCSDiscussing adaptations to the comprehensive care model in multiple sclerosis, the founder of MS Bites commented on the need to consistently incorporate dietitians. [WATCH TIME: 6 minutes]
Latest:
Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MSThe director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]
Latest:
Using the Cognitive Stress Test to Distinguish Pre-MCI and Amnestic MCI: Leeron Nahmias, BSThe medical student at Nova Southeastern University provided insight on a new innovative tool called the Cognitive Stress Test that can help distinguish different cognitive states for older adults. [WATCH TIME: 6 minutes]
Latest:
Enhancing Initiation and Titration Strategies for Neuromodulation in Lennox-Gastaut Syndrome: Depobam Samanta, MD, MS, FAAP, FAESThe medical director of the Arkansas Children’s Comprehensive Epilepsy Program detailed advancements and strategies in using neuromodulation for LGS, as well as the future research needed to expand these approaches. [WATCH TIME: 4 minutes]
Latest:
CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 VaccineDespite previous data suggesting no link, the CDC and FDA will continue to review all evidence for possible increased risk of ischemic stroke.
Latest:
CIDP Treatment Options and Treatment Selection CriteriaPanelists discuss how selecting the appropriate treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) involves considering disease characteristics, patient preferences, and treatment response, with options ranging from intravenous immunoglobulin (IVIg) to emerging therapies based on individual needs and safety considerations.
Latest:
Empowering Patient Voice in Epilepsy Treatment and Strategies for Seizure Freedom: Patrick Kwan, MD, PhD, FRCPThe professor of neurology in the department of neuroscience at Monash University discussed implementation strategies for treatment approaches to achieve seizure freedom in patients with epilepsy. [WATCH TIME: 5 minutes]
Latest:
Paramagnetic Rim Lesions and Immune Profiling in Multiple Sclerosis Progression: Simon Thebault, MD, PhDThe assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]
Latest:
Using a Novel Educational Intervention to Improve Overall Knowledge of Headache: Sara Pavitt, MDThe chief of headache at UT Austin Dell Children’s Hospital provided insight on a new series designed to deliver longitudinal comprehensive pediatric headache education. [WATCH TIME: 3 minutes]
Latest:
The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhDThe director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]
Latest:
The Potential of Embolization as a Treatment Approach for Subdural Hematomas: Jason M. Davies, MD, PhDThe assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the efficacy and safety of using embolization as a promising treatment for subdural hematomas. [WATCH TIME: 3 minutes]
Latest:
Anti-CD20 Therapies for MSAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.
Latest:
Understanding Stathmin-2’s Impact on ALS Motor and Sensory Denervation: Cathleen M. Lutz, PhDThe vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]
Latest:
Building the Next Generation of Migraine Specialists: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHSThe chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]
Latest:
Real-World Effectiveness and Safety of Monoclonal Antibodies in NMOSD: Amy Kunchok, MD, PhDThe staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]
Latest:
Building Your Acute Migraine ToolboxPlagued by a long history of under- and inadequate treatment, clinicians have more options than ever to craft a personalized, effective plan for their patients.
Latest:
Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhDThe neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]
Latest:
Occurrence of Late-Onset Neurotropenia After Anti-CD20 Therapy: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCIThe senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]
Latest:
How MR Fingerprinting Can Improve Epilepsy Surgery: Irene Wang, PhDThe research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]
Latest:
Potential of Advancing Neurofibromatosis Care With Investigational MirdametinibJim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization of mirdametinib, a promising treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Latest:
Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPHThe director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]
Latest:
Therapeutic Potential of Combination Strategies to Treat Alzheimer Disease: Lloyd Tran, PhDThe chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]
Latest:
The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MDThe neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]
Latest:
AI in Academic Neurology: A Chat With ChatGPT-4L. John Greenfield Jr, MD, PhD, “spoke” about the future of artificial intelligence in neurology with ChatGPT-4—one of the largest language modules that have grabbed the field’s interest.
Latest:
Steps to Validate Stathmin-2 as an ALS-Specific Biomarker: Cathleen Lutz, PhDThe vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]
Latest:
Challenges of Shared Decision-Making in the Management of Multiple SclerosisAlthough challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.
Latest:
The Importance of Sleep Medicine Education: Anita Shelgikar, MD, MHPEThe clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]
Latest:
SPONSORED ARTICLE TEMPLATEThis is the deck of the article. It can be used to provide further context to the headline and provides search engines with summary text for social posts.
